The antidiabetic effects of thiazolidinedione (TZD) drugs may be mediated in part by a molecular interaction with the constituent proteins of the mitochondrial pyruvate carrier complex (MPC1 and MPC2). We examined the ability of a mutant mouse strain expressing an N-terminal truncation of MPC2 (Mpc2 16 mice) to respond to TZD treatment. between TZDs and MPC2 is not affected by loss of the N-terminal 16 amino acids nor are these residues required for the insulin-sensitizing effects of these compounds.
Introduction
Thiazolidinediones (TZDs) have been in clinical use as a treatment for diabetes since the 1990s. Thiazolidinediones are effective insulin-sensitizing and anti-inflammatory agents, but their use has been curtailed by several associated side-effects (Colca & Kletzien, 2006) . The identified and canonical mechanism of action for TZDs is via their effects as ligands for a nuclear receptor, the peroxisome proliferator-activated receptor γ (PPARγ; Lehmann et al. 1995; Soccio et al. 2014) . Activation of PPARγ drives fat deposition in adipocytes, is anti-inflammatory and stimulates production of adipokines, including adiponectin, with beneficial metabolic effects (Halberg et al. 2008; Riera-Guardia & Rothenbacher, 2008) . In addition, through use of mice with tissue-specific knockout of PPARγ, it has been demonstrated that several of the known side-effects of TZDs are also mediated through this nuclear receptor (Duan et al. 2005; Guan et al. 2005; Zhang et al. 2005) . However, there is strong evidence that TZDs also have PPARγ-independent actions that might have beneficial effects on metabolism (Adams et al. 1998; Raman et al. 1998; Raman & Judd, 2000; Chen et al. 2012) . We and others have postulated that if the insulin-sensitizing effects of TZDs could be separated from the pure agonism of PPARγ, the resulting compounds might be effective antidiabetic agents with a better safety profile. To this end, several TZDs with very low affinity for PPARγ have been developed and used in phase 2 clinical trials as insulin sensitizers (Colca et al. 2013b) .
One alternative mode of action for TZDs is through binding to the mitochondrial pyruvate carrier (MPC) in the inner mitochondrial membrane (Colca et al. 2013a ). The MPC is made up of two proteins, MPC1 and MPC2, which form a heteroligomeric complex (Bricker et al. 2012; Herzig et al. 2012) . This complex mediates the transport of pyruvate into the mitochondrial matrix, which is required for its metabolism. Several studies now suggest that TZDs bind to the MPC directly and inhibit pyruvate transport to elicit effects on mitochondrial oxidative metabolism (Divakaruni et al. 2013; Colca et al. 2013a; . Binding and acute inhibitory effects on downstream pyruvate metabolism have been demonstrated for both current clinically used TZDs (rosiglitazone and pioglitazone) and next-generation PPARγ-sparing TZDs, such as MSDC-0602 (Divakaruni et al. 2013; Colca et al. 2013a; . However, it is not yet clear whether binding to the MPC and the resultant effects on mitochondrial metabolism are involved in the PPARγ-independent effects of TZDs on insulin sensitivity and systemic metabolism.
In order to test whether the interaction with the MPC is required for the insulin-sensitizing effects of TZDs, we recently generated a constitutive knockout for MPC2 (Vigueira et al. 2014) . Given that the stability of the MPC complex requires both MPC1 and MPC2, this essentially results in a double or complete MPC knockout. Global and constitutive MPC deficiency is lethal in mice at early embryonic stages (Vigueira et al. 2014; Bowman et al. 2016; Li et al. 2016; Vanderperre et al. 2016) , which is incompatible with studying the relationship between the MPC and TZDs in vivo. Fortuitously, owing to an alternative translational start site in MPC2, we also unexpectedly generated mice expressing a protein lacking the first 16 amino acids (Mpc2 16 mice; Vigueira et al. 2014) . Mpc2 16 mice have a reduced abundance of both MPC1 and MPC2 protein compared with wild-type (WT) mice, but the remaining truncated MPC2 protein does properly localize to the inner mitochondrial membrane (Vigueira et al. 2014) . These mice are viable, outwardly normal, and exhibit moderate (ß30%) reductions in mitochondrial pyruvate metabolism (Vigueira et al. 2014) . Besides increased plasma lactate concentrations, the primary phenotype of the Mpc2 16 mice is glucose intolerance that is attributable to defective insulin secretion by pancreatic β-cells (Vigueira et al. 2014) .
Given the viability of this model with partial MPC deficiency, we sought to evaluate the requirement of these 16 amino acids of MPC2 and the effects of MPC2 hypomorphism on TZD responses. In vivo studies conducted with WT and Mpc2 16 mice showed that the ability of pioglitazone (PIO) and MSDC-0602 to confer insulin sensitization in high-fat (HF) diet-fed mice was not affected by MPC2 hypomorphism. Moreover, studies conducted in vitro showed that N-terminal 16 amino acid truncation of MPC2 failed to abolish the interaction between TZDs and the MPC or affect the ability of these drugs to modulate mitochondrial pyruvate metabolism. This suggests that loss of the N-terminal 16 amino acids of MPC2 does not affect the interaction with or insulin-sensitizing actions of TZDs.
Methods

Ethical approval
All vertebrate animal experiments were approved by the Animal Studies Committee of the Washington University School of Medicine and carried out according to the approved protocol (#20110101) and the principles and regulations described by Grundy (2015) .
Animal studies
Mice homozygous for the Mpc2 16 allele have been described previously (Vigueira et al. 2014) . Deletion of the original Mpc2 translational start codon led to enforcement of an alternative start codon that encoded an MPC2 protein lacking the N-terminal 16 amino acids (Vigueira et al. 2014) . Mice were generated and studied in a pure C57BL/6 background, and only male mice were studied in the experiments described. Six-to 8-week-old mice were placed on purified diet providing 10% (Research Diets Inc., New Brunswick, NJ, USA, D12450B) or 60% (Research Diets Inc., D12492) of its calories as fat and remained on these diets for 10 weeks before initiation of TZD therapy. Subsets of mice were then randomized to remain untreated or to receive TZDs that were incorporated into the 60% fat chow (pioglitazone, 300 p.p.m. and MSDC-0602, 331 p.p.m.) for an additional 4 weeks (Fig. 1A) . Previous work has shown that this concentration of MSDC-0602 in the diet resulted in a blood concentration of 2-5 μM of drug in obese mice . Ad libitum access to food was provided for the duration of the experiment, and body weights were monitored weekly.
After 8 weeks of a 10 or 60% fat diet challenge and again after 3 weeks of treatment with TZDs, mice were briefly sedated by I.P. injection of a cocktail of ketamine [VEDCO Inc., Saint Joseph, MO, USA (87 mg kg −1 )] and xylazine [Akorn Animal Health, Lake Forest, IL, USA (13 mg kg −1 )] and subjected to dual-energy X-ray absorptiometry (DEXA) analysis to determine the percentage body fat as previously described (Finck et al. 2005) .
Glucose tolerance tests were conducted in drug-naive mice after 9 weeks of a 10 or 60% fat diet challenge and again after 2 weeks of treatment with TZDs (Fig. 1A ). Mice were fasted overnight for 16 h on aspen chip bedding, and glucose tolerance tests were performed as previously reported (Vigueira et al. 2014; McCommis et al. 2016a) . Glucose concentrations were monitored using blood acquired from a single tail snip and gentle milking. Blood glucose area under the curve (AUC) was calculated using the trapezoidal rule.
After a 3 day diet treatment and acclimation period, the activity of 18-to 19-week-old, male, WT, C57BL6/J, diet-induced obese mice was measured for 5 days while being fed control high-fat diet or a high-fat diet containing MSDC-0602 or pioglitazone. Activity levels were determined using an InfraMot activity system (TSE systems, Chesterfield, MO, USA), with the light period from 06.00-18.00 h and dark period 18.00-06.00 h.
After 4 weeks of TZD treatment, mice were killed by CO 2 sedation and asphyxiation, and blood was collected from the inferior vena cava into EDTA-coated syringes. Plasma was collected after blood centrifugation. Tissues were collected and snap-frozen for later analysis.
Quantitative RT-PCR
Total RNA was isolated from epididymal white adipose tissue using the RNAzol method (Tel-Test, Friendswood, TX, USA), and cDNA was synthesized with the Vilo reverse transcription kit (Invitrogen, Carlsbad, CA, USA). Real-time PCR was performed using the ABI PRISM 7500 sequence detection system and the SYBR green kit (Applied Biosystems, Foster City, CA, USA). Arbitrary units of target mRNA were corrected by measuring the levels of 36B4 RNA. Sequences of the oligonucleotides used in qRT-PCR analyses are available on request.
Plasma measurements
The insulin content was analysed by Singulex assay by the Washington University Immunoassay Core of the Diabetes Research Center. Plasma triglyceride and cholesterol concentrations were measured by Infinity colorimetric assay kits (Thermo Fisher Scientific, Waltham, MA, USA). Plasma non-esterified fatty acid concentrations were measured using an enzymatic assay (Wako Diagnostics, Mountain View, CA, USA). Plasma alanine transaminase (ALT) activity was measured by kinetic absorbance assays (Teco Diagnostics, Anaheim, CA, USA).
Liver triglyceride quantification
Liver triglyceride was measured by homogenizing 100 mg liver tissue in saline and solubilizing lipid with 0.5% sodium deoxycholate. Liver triglyceride was then determined by colorimetric assay (Thermo Fisher Scientific) as performed previously (Vigueira et al. 2014; .
REporter Sensitive to PYRuvate (RESPYR) assay
pWPT lentiviral vectors expressing cDNA encoding human MPC2 fused to RLuc8 [bioluminescence resonance energy transfer (BRET) donor] and human MPC1 fused to Venus (BRET acceptor) have been described (Compan et al. 2015; McCommis et al. 2016a) . hMPC2 16-L17M constructs were generated using a QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA). The nucleotides encoding the first 16 residues of the P. A. Vigueira and others MPC2 region of the protein were deleted first, and then a second round of mutagenesis was performed to insert a new start codon (L17M) to mirror the MPC2 16 mouse protein using the manufacturer's recommended protocol. Site-directed mutagenesis primers used to delete the first 16 residues were 5 -CTCC ACTTTATCGAGGGTGGCCTCGAGGC-3 and 5 -GCCT CGAGGCCACCCTCGATAAAGTGGAG-3 . Site-directed mutagenesis primers used for the L17M mutation were 5 -CAGCTCCACTTTATCCATGGTGGCCTCGAGGCT-3 and 5 -AGCCTCGAGGCCACCATGGATAAAGTGGAGC TG-3 . Successful mutagenesis was verified by DNA sequencing by the Protein and Nucleic Acid Chemistry Laboratory at Washington University in St Louis. Viruses containing the mutant plasmids were generated, and MPC2-knockout (KO) HEK293T cells were transformed using the same methods as with the WT plasmids. Briefly, MPC2-KO HEK293T cells (described below) were transiently transfected with WT and hMPC2 16-L17M RESPYR constructs by using Lipofectamine according to the instructions of the manufacturer. Twenty-four hours post-transfection, HEK293T cells were seeded in white 96-well plates 48 h before recording using Phenol Red-free Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1× MEM non-essential amino acids. Assays were performed 48 h post-transfection and analysed as described by Compan et al. (2015) and McCommis et al. (2016a) . Luminescence was measured using a plate reader (Biotek Synergy 2, Biotek, Winooski, VT, USA) at 460 and 528 nm at 37°C.
Oxygraph respiration
Mitochondrial respiration of HEK293T cells was measured using an Oxygraph O2k (Oroboros Instruments). Cells (2 × 10 6 ) were suspended in 2 ml Mir05 respiration buffer and permeabilized with 20 μg digitonin. Respiratory substrates were 5 mM pyruvate or 2 mM malate in the presence or absence of 1 mM ADP. After establishment of maximal pyruvate or malate respiration with ADP, 20 μM MSDC-0602 was injected into the respiratory chamber to test acute effects on pyruvate-mediated respiration.
Cell culture and generation of MPC2 knockout and hypomorphic MPC2 cell lines using clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 systems
HEK293T cells were tested using the PlasmoTest TM Mycoplasma Detection Kit according to the manufacturer's instructions (InvivoGen, San Diego, CA, USA) and found to be mycoplasma free. Lines were maintained in Dulbecco's modified Eagle's medium containing 4.5 g l −1 glucose supplemented with 10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA, USA), 1 mM pyruvate, 2 mM glutamine, 2 mM Glutamax, 1 mM citrate, 50 μg ml −1 uridine and 1 × penicillin-streptomycin (Thermo Fisher Scientific) at 37°C in a humidified 5% CO 2 atmosphere. CRISPR/Cas9 targeting constructs were generated by subcloning oligonucleotides (listed below) into the BbsI sites of pSpCas9(BB)-2A-GFP (PX458; Addgene# 48138). HEK293T cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Two control, non-targeted HEK293T cell lines were generated by co-transfection with pSpCas9(BB)-2A-GFP backbone lacking single guide RNA (sgRNA) and PQCXIP backbone at 9:1 DNA ratio. MPC2KO-1, MPC2KO-2 and MPC222 were generated by co-transfection with PX458 harbouring either sgRNA pair #1 or pair #2 and PQCXIP with proportions of 4.5:4.5:1. The sgRNAs were as follows: MPC2KO-1 sgRNA1, 5 -CACCGG CTGCCAACGATCCCTCGG-3 and 3 -CCGACGGTTGC TAGGGAGCCCAAA-5 ; sgRNA2, 5 -CACCGGAGCTGA CTTGAGATACGT-3 and 3 -CCTCGACTGAACTCTAT GCACAAA-5 ; MPC2KO-2 sgRNA1, 5 -CACCGCTTTT CGGTTCACAGCGGGC-3 and 3 -CGAAAAGCCAAGT GTCGCCCGCAAA-5 ; sgRNA2, 5 -CACCGACTTGAG ATACGTTGGCTTAGG-3 and 3 -CTGAACTCTATGCAA CCGAATCCCAAA-5 ; MPC222 sgRNA1, 5 -CACCGC GGACGCGAGTCGTCGTGGC-3 and 3 -CGCCTGCGC TCAGCAGCACCGCAAA-5 ; and sgRNA2, 5 -CACCG CCACCGGCTCCTCGATAAAG-3 and 3 -CGGTGGCC GAGGAGCTATTTCCAAA-5 .
At 72 h post-transfection, cells were selected using 2 μg ml −1 puromycin for 72 h. After 48 h recovery in growth media, cells were monoclonally diluted into 96-well plates for growth of monoclonal lines. Upon reaching 80% confluency, monoclonal lines were divided into two portions to be used for genotyping and maintenance. Genomic DNA was extracted using QuickExtract TM DNA Extraction Solution (Epicentre, Madison, WI, USA), according to the manufacturer's protocol. Cell lines were genotyped by PCR on extracted genomic DNA using the following primers: 5 -CAGCGCA GACTTGGTGAGG-3 and 3 -GTGCTGAGGTTGGGTT TGGA-5 .
Western blots
CRISPR/Cas9-edited cells were lysed in Laemmli buffer containing 62.5 mM Tris pH 6.8, 2% SDS (m/v), 10% glycerol (v/v) and dithiothreitol (0.1 μM) and quantified using the Pierce TM BCA Protein Assay Kit (Thermo Fisher Scientific). Equal amounts of protein lysates were prepared in Laemmli buffer supplemented with Bromophenol Blue and boiled at 95°C for 10 min. Lysates were resolved on 10% Tricine-SDS-PAGE gels using a Mini-PROTEAN Tetra Cell running system (Bio Rad, Hercules, CA, USA). The Trans-Blot transfer cell system (Bio Rad) was used to transfer samples to nitrocellulose membranes (GE Healthcare, Marlborough, MA, USA; 10600001). Membranes were blocked with 5% (m/v) non-fat dry milk in 50 mM Tris and 150 mM NaCl (TBS) for 1 h, incubated with primary antibodies against MPC2 (1:1000; Cell Signaling Technology, Danvers, MA, USA; #46141), MPC1 (1:1000; Cell Signaling Technology; #14462), uncoupling protein 1 (UCP1; 1:1000; Abcam, Cambridge, UK; #10983), α-tubulin (1;1000; Sigma Aldrich, St. Louis, MO, USA; #T6074) and voltage-dependent anion channel (VDAC; 1:1000; Cell Signaling Technology; #4661) overnight at 4°C, and incubated with fluorescent goat anti-rabbit DyLight 800 secondary antibody (1:10,000; Thermo Fisher; 35571) for 1 h. Membranes were imaged using the Odyssey CLx system (Li-Cor Biosciences, Lincoln, NE, USA).
Statistical analyses
The P values for pairwise comparisons were calculated using un-paired Student's t test. The P values for RESPYR P. A. Vigueira and others curves were calculated using repeated-measures, two-way ANOVA coupled to Tukey's multiple comparison tests. In all experiments, P ࣘ 0.05 was used to determine significant difference. All quantitative data are represented as the mean ± SD.
Results
Wild-type and Mpc2 16 mice exhibit a similar response to high-fat diet feeding
We evaluated the insulin-sensitizing effects of pioglitazone and MSDC-0602 in vivo in WT and Mpc2 16 mice to determine whether the first 16 amino acids of MPC2 were required for drug effects. The WT and Mpc2 16 mice were placed on a high-fat (HF; 60% of calories from fat) or low fat control (LF; 10% of calories from fat) diet. At the start of the dietary treatments, Mpc2 16 mice weighed slightly less than WT control animals, 21.3 ± 2.2 versus 22.8 ± 1.9 g, respectively (P < 0.001). No differences were observed for any parameter examined between genotypes in the mice fed LF diet. On the HF diet, Mpc2 16 mice tended to gain less weight beginning at week 7 of the trial (Fig. 1B) . However, the percentage body fat, as assessed by DEXA, was not significantly different between the two genotypes (Fig. 1C ). In addition, HF feeding caused glucose intolerance in mice of both genotypes (Fig. 1D) . No effect of genotype on glucose tolerance was detected in mice on either dietary regimen.
Mpc2 16 mice are not refractory to the insulin-sensitizing effects of TZDs
We randomly assigned HF-fed WT and Mpc2 16 mice either to remain on the regular HF diet or to be given ad libitum access to HF diet containing pioglitazone (+PIO) or MSDC-0602 (+0602) for an additional 4 weeks. Interestingly, while mice fed regular HF diet or HF diet containing PIO continued to gain weight or remained static, all mice fed MSDC-0602 lost a notable amount of weight ( Fig. 2A and B) . This loss of body weight occurred within the first week of MSDC-0602 feeding and is similar to another recent study we conducted with MSDC-0602 (McCommis et al. 2016b) . Weight loss was not associated with increased locomotor activity in WT mice (Fig. 2C) or an overt reduction in food intake in mice of either genotype (Fig. 2D ) in MSDC-0602-treated mice compared with HF-fed control animals. However, there was a non-significant tendency towards decreased activity counts in mice given PIO compared with untreated control mice. Administration of MSDC-0602 caused a reduction in percentage body fat in both WT and Mpc2 16 mice after 3 weeks of TZD treatment (Fig. 2E) . Although PIO had no effect on adiposity in WT mice, Mpc2 16 mice in the pioglitazone treatment group exhibited decreased weight gain and adiposity compared with HF diet alone ( Fig. 2B and E) . This reduction in adiposity could be attributable to reduced consumption of the PIO-containing diet compared with HF diet by the Mpc2 16 mice for reasons that are not clear. Although unlikely, this could be a gene-drug interaction leading to a conditioned taste aversion, but is more likely to be a type 1 statistical error.
Two weeks of either PIO or MSDC-0602 feeding markedly improved the glucose tolerance of HF-fed mice and, in fact, returned the blood glucose area under the curve values to levels similar to those of lean control animals ( Fig. 3A and B) . The effects of PIO and MSDC-0602 on glucose tolerance were again not affected by loss of the first 16 amino acids of MPC2 in Mpc2 16 mice (Fig. 3A and B) . These data suggest that the N-terminus of MPC2 does not mediate the effects of PIO or MSDC-0602 on glucose tolerance.
Two weeks after the glucose tolerance tests, mice were killed in order to measure tissue and plasma parameters. Both PIO and MSDC-0602 treatment led to improvements in a number of plasma parameters that were deranged in the HF-fed mice. Specifically, treatment with either TZD lowered plasma triglyceride, cholesterol, and free fatty acid concentrations compared with HF-fed comparators (Table 1) . Thiazolidinedione treatment reduced the plasma insulin concentration and increased the adiponectin concentration (Table 1) . These responses were all also observed in Mpc2 16 mice, again suggesting that the N-terminus of MPC2 does not mediate these beneficial metabolic effects of TZDs. Administration of either PIO or MSDC-0602 markedly reduced the hepatic steatosis observed in HF-fed mice, and this was observed in mice of either genotype (Fig. 3C) . Thiazolidinedione administration also significantly lowered circulating transaminase (ALT) in mice of both genotypes (Table 1) .
Effects of TZDs on adipose tissue expression of inflammatory and mitochondrial biogenesis markers
Thiazolidinediones are known to reduce macrophage infiltration and adipose tissue pro-inflammatory cytokine expression. The administration of HF diet robustly induced the expression of the macrophage markers Cd68 and F4/80 (Emr1), the chemoattractant Mcp1 and the pro-inflammatory cytokine Tnfa in the epididymal white adipose tissue (Fig. 4) . Treatment with PIO or MSDC-0602 suppressed the elevated expression of most of these genes in mice of both genotypes. Consistent with the plasma data, the expression of adiponectin (Adipoq) was also rescued by treatment with either TZD and was not affected by genotype.
Among the genes whose expression was downregulated by obesity and stimulated by TZD treatment were the Thiazolidinediones and the pyruvate carrier , HF diet supplemented with pioglitazone (PIO)] determined using an infrared-sensing device (InfraMot) during the dark phase of the diurnal cycle (18.00-06.00 h), light phase (06.00-18.00 h), and the sum of both. Values are presented as the mean ± SD. HF, n = 11; 0602, n = 12; PIO, n = 12. D, consumption of food by WT and Mpc2 16 mice on diets that were low fat (LF), high-fat (HF), HF containing pioglitazone (HF + PIO), or HF containing MSDC-0602 (HF + 0602) for the first 2 weeks of TZD administration. E, body fat percentage determined by dual-energy X-ray absorptiometry (DEXA) analysis after 3 weeks of TZD treatment. WT LF, n = 15; Mpc2 16 LF, n = 9; WT HF, n = 14; Mpc2 16 HF, n = 9; WT HF + PIO, n = 13; Mpc2 16 HF + PIO, n = 8; WT HF + 0602, n = 13; Mpc2 16 HF + 0602, n = 9. * P < 0.05 versus LF-fed group. † P < 0.05 versus HF-fed group.
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genes encoding MPC1 and MPC2 (Fig. 5A ). Western blotting confirmed that these changes in gene expression also resulted in corresponding changes in MPC1 and MPC2 protein abundance (Fig. 5B) . Thiazolidinediones are also known to stimulate mitochondrial biogenesis and 'browning' of white adipose tissue. In addition, TZDs stimulated a marked activation of Ucp1 expression in the epididymal fat pad (Fig. 5C ), which was also confirmed at the protein level ( Fig. 5B and C) . Consistent with a browning of this depot, the expression of Prdm16 and Ppargc1a, which transcriptionally activate the browning programme, was also induced (Fig. 6) . Lastly, expression of several other genes associated with a thermogenic transcriptional programme was increased in epididymal fat by administration of pioglitazone or MSDC-0602 (Cidea, Cox2 and Acadm; Fig. 6 ). In all instances, the response to TZD administration was unaffected by mouse genotype.
The N-terminus of MPC2 is dispensable for interaction with TZD and effects on pyruvate metabolism
The recently described, BRET-based MPC activity system known as RESPYR (Compan et al. 2015) can also be used to detect interactions with small molecule competitive inhibitors of MPC activity (McCommis et al. 2016b ). As we have previously described, addition of UK-5099, a potent and specific MPC inhibitor, or MSDC-0602 caused a dramatic and immediate increase in RESPYR activity in HEK293 cells (Fig. 7A, left panel) . To determine whether loss of the first 16 amino acids affected this interaction, an MPC2 16 mutant MPC2-Rluc8 fusion protein was generated. The mutant MPC2-Rluc8 fusion protein was expressed at levels similar to the WT fusion protein (Fig. 7B) . To eliminate the potential for contribution of endogenous MPC2 to the MPC complex, these studies were conducted in HEK293T cells that were completely MPC2 null (described in Fig. 7C ). Loss of the first 16 amino acids did not prevent activation by pyruvate, MSDC-0602 or UK5099 (Fig. 7A) . We also determined the effect of MPC2 truncation on the ability of MSDC-0602 to suppress pyruvate-mediated respiration by permeabilized cells. To this end, HEK293T cells that were WT, completely MPC2 null or expressing the endogenous human equivalent (MPC2 22) of the mouse Mpc2 16 allele were generated by using CRISPR/Cas9 (Fig. 7C) . We found that complete loss of MPC2 markedly reduced maximal pyruvate-stimulated respiration and rendered cells insensitive to the inhibitory effects of MSDC-0602 on oxygen consumption (Fig. 7D) . In contrast, loss of the first 22 amino acids led to only a moderate reduction in maximal pyruvate respiration, and cells expressing this allele fully responded to MSDC-0602 with reduced oxygen consumption (Fig. 7D) . Collectively, these data suggest that the interaction of TZDs with the MPC complex does not require the first 16 amino acids of MPC2 and that loss of the N-terminus of MPC2 does not abrogate the effects of TZD on pyruvate metabolism.
Discussion
Recent work has suggested that TZDs may have insulin-sensitizing effects that are independent of their canonical roles as ligands for PPARγ. One potential alternative mechanism that has emerged recently is an interaction with the MPC complex and subsequent attenuation of mitochondrial pyruvate metabolism. However, the mechanistic details of this interaction remain unresolved. In this work, we used mice expressing an MPC2 protein that lacks the N-terminal 16 amino acids to evaluate the effects of this MPC2 truncation on the metabolic effects of PIO and the PPARγ-sparing TZD, MSDC-0602. We found that MPC2 hypomorphic mice were not refractory to the insulin-sensitizing effects of TZDs. Loss of the first 16 amino acids of MPC2 also did not affect the interaction of TZDs with the MPC complex nor did it affect the ability to modulate pyruvate-mediated respiration. In contrast, complete deletion of MPC2 led to a loss of the inhibitory effect of MSDC-0602 on pyruvate-mediated respiration, indicating that this effect on metabolism is MPC dependent. Thus, the N-terminus of MPC2 is not required for the insulin-sensitizing effect of TZDs. However, it is still not clear whether the entire MPC complex is required for TZD-mediated insulin sensitization.
Given that the inner mitochondrial matrix is impermeable to charged molecules, such as pyruvate, it has long been hypothesized that a carrier-based mechanism for pyruvate import into the mitochondrial matrix must exist . However, the identity of this carrier was not known until recently, P. A. Vigueira and others when it was discovered by two groups evaluating the functional roles of mitochondrial proteins that are highly conserved across deeply diverged lineages (Bricker et al. 2012; Herzig et al. 2012) . The mitochondrial pyruvate carrier mediates an important step in intermediary metabolism. The majority of pyruvate generation occurs via glycolysis and by oxidation of lactate by lactate dehydrogenase in the cytosol of the cell. The enzymes that further metabolize pyruvate, pyruvate dehydrogenase and pyruvate carboxylase, are localized to the mitochondrial matrix. Thus, the MPC-mediated import of pyruvate into the mitochondria is required for high rates of metabolic flux through anabolic and catabolic pathways.
In some tissues, the mechanisms by which inhibition of mitochondrial pyruvate metabolism would lead to glucose-lowering effects can be clearly identified. For example, MPC inhibition in hepatocytes leads to reduced flux through gluconeogenic pathways (Gray et al. 2015; , and we have shown that liver MPC2 deletion protects mice from the development of diabetes . In other organs, it
is not yet clear how inhibition of the MPC might lead to insulin-sensitizing effects. Potentially, modulation of pyruvate flux leads to alterations in the cellular redox status and/or synthesis of NAD + as a byproduct of lactate synthesis from pyruvate. It might also reduce mitochondrial production of reactive oxygen species. On the contrary, interaction with the MPC and/or effects on pyruvate metabolism may not be involved in all of the mitochondrial and insulin-sensitizing effects of TZDs. Indeed, a number of potentially direct mitochondrial effects of these drugs have been identified and warrant additional exploration (Brunmair et al. 2004; Feinstein et al. 2005) . 
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Data from this and previous studies suggest that it may be necessary to disrupt the MPC complex completely in order to determine the effect on insulin sensitization in vivo. Unfortunately, constitutive knockout of MPC2, which destabilizes the MPC complex and essentially leads to double deletion of MPC1 and MPC2 protein, leads to early embryonic lethality in mice (Vigueira et al. 2014) . In addition, mice with whole-body, tamoxifen-inducible deletion of MPC2 (Lam et al. 2016 ) also succumb within a week of tamoxifen-induced MPC2 deletion (K. McCommis, unpublished observation). Although mice with liver-specific or β-cell specific MPC2 deletion (McCommis et al. 2016a ) are viable and relatively normal, their utility in determining the requirement for the MPC in the insulin-sensitizing effects of TZDs is limited because of effects in other tissues, including adipocytes. Thus, defining the role of MPC in TZD-mediated insulin sensitization is very challenging with existing molecular genetic tools. Identifying the residues required for TZD interaction with the MPC complex, as we attempted to do here, would be the first step towards making mutant alleles that might still be competent for pyruvate transport and support life but would be refractory to TZD binding. These tools could allow for the testing of the requirement for the MPC in TZD effects, which might not be identical in all cell types.
We have previously shown that Mpc2 16 mice are glucose intolerant as a result of reduced insulin secretion (Vigueira et al. 2014) , but that effect was not evident in the present study even in LF diet-fed mice. In that previous work, the absolute differences in blood glucose during glucose tolerance tests were significantly, but not dramatically, different with an 'n' of 14. Our additional studies conducted with β-cell MPC2 KO mice (McCommis et al. 2016a ) very strongly support the veracity of the glucose intolerance phenotype we observed in the Mpc2 16 mice, and we believe that these published findings are accurate. However, an effect of the Mpc2 16 genotype on glucose tolerance was not observed in the LF group in the present study. There are a number of potential explanations for this. The previous study used female mice, whereas the present study used male mice, and the mice used in this study were also somewhat older at the time of the glucose tolerance test studies. Perhaps the most important difference was that the LF control diet used in the present study is a purified diet matched to the HF diet, whereas mice in the previous study were fed standard mouse chow. The purified diet contains a considerable amount of simple sugar (sucrose), whereas the chow does not, and this could affect the insulin sensitivity and glucose tolerance of the control animals. We cannot pinpoint one of these differences as a definitive explanation, but these are all potential factors.
In conclusion, the present study aimed to evaluate the effects of partial deletion of the MPC2 protein on the binding and insulin-sensitizing effects of TZD insulin sensitizers. The present results confirmed that a TZD with very low affinity for PPARγ still had potent insulin-sensitizing effects and led to browning of white adipose tissue in diet-induced obese mice. The data also indicate that pioglitazone and MSDC-0602 acutely suppress mitochondrial pyruvate metabolism and, using a BRET-based approach, that these compounds interact directly with the MPC complex. However, it was determined that deletion of the N-terminus of MPC2 did not affect the response to TZDs nor did it disrupt the interaction between the compound and the MPC complex. Further study is required to elucidate fully whether or how the MPC complex is involved in the cellular-specific, non-genomic insulin-sensitizing effects of TZDs.
